Patents by Inventor Clifford John Harris

Clifford John Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections
    Patent number: 8362018
    Abstract: Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: January 29, 2013
    Assignee: Biofocus DPI, Ltd.
    Inventors: Angus MacLeod, Dale Robert Mitchell, Nicholas John Palmer, Michael Daniel Goldsmith, Clifford John Harris, Christophe Claude Parsy
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8178530
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 15, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus MacLeod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8173656
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 8, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110218178
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Application
    Filed: December 16, 2010
    Publication date: September 8, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • IMIDAZOPYRAZINE COMPOUNDS
    Publication number: 20110166147
    Abstract: Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.
    Type: Application
    Filed: August 20, 2008
    Publication date: July 7, 2011
    Inventors: Angus Macleod, Dale Robert Mitchell, Nicholas John Palmer, Michael Daniel Goldsmith, Clifford John Harris, Christophe Claude Parsy
  • IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110092497
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Application
    Filed: December 16, 2010
    Publication date: April 21, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 7893058
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: February 22, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus MacLeod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Pyrazolo[1,5-a]pyrimidine derivatives
    Patent number: 7667036
    Abstract: The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: February 23, 2010
    Assignee: Teijin Pharma Limited
    Inventors: Tomomi Kosugi, Minoru Imai, Hiroaki Makino, Mika Takakuwa, Gen Unoki, Kenichiro Kataoka, Dale Robert Mitchell, Donald James Simpson, Clifford John Harris, Joelle Le, Yuko Yamakoshi